Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbio... Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. 詳細を表示
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md., Feb. 9, 2022 ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE...
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences...
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md., Jan. 26, 2022 ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic...
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate...
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical...
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET...
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical...
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by...
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md., Sept. 21, 2021 ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/...
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 銘柄コード | 株価 | 出来高 |
|---|---|---|
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 32.45 (8.20%) | 51.76M |
| MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 13.28 (17.11%) | 51.57M |
| SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 18.33 (-8.03%) | 43.15M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5.9199 (-3.27%) | 41.56M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 1.9697 (-12.07%) | 40.52M |
SierraPacificRising
4分前
snupoled
4分前
Huggy Bear
4分前
iclight
5分前
Nukemtiltheyglow
5分前
Screech691
5分前
Aquahoya
5分前
TESLIN
5分前
Invest-in-America
6分前
Hawk05
6分前
BullNBear52
6分前
WeTheMarket
6分前
Argeoz
6分前
TN Trash
6分前
MasterBlastr
7分前
StocksGoneWild
7分前
dreamaker56
7分前
Structural_Biologist
7分前
CrashOverride
7分前
Lone Clone
7分前
misterfishman
7分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
